TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35143800
Drug: Methotrexate 25
Normalized name: methotrexate 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 25 mg weekly (for those who switched treatment)
Study: 35143800
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil 1.5 g twice daily (for those who switched treatment)
Study: 32617631
Drug: Oral opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral opioid rescue medication (hydromorphone) in Cohort 1 (C1)
Study: 32617631
Drug: Patient-controlled intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled intravenous analgesia (PCIA) with piritramide in Cohort 2 (C2)
Study: 35551086
Drug: Irreversible electroporation
Normalized name: Adult allogeneic CD4+ and CD8+ enriched T cells transduced with an anti-CD19 chimeric antigen receptor (CAR) that is site-specific integrated into the cellular genome. Adult allogeneic CD4+ and CD8+ enriched T cells, gene edited through the electroporati
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irreversible electroporation (IRE) followed by further chemotherapy if indicated
Study: 35551086
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (standard of care)
Study: 33774192
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution with conventional cementation system (etch‐and‐rinse adhesive)
Study: 33774192
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution with conventional cementation system (universal adhesive)
Study: 36169086
Drug: Methylprednisolone 250
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone 250 mg once daily for 3 days
Study: 36169086
Drug: Dexamethasone 6
Normalized name: dexamethasone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 6 mg once daily for up to 10 days
Study: 33882590
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of aspirin daily at bedtime
Study: 34189446
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care plus oral IVM at 0.6 mg/kg/day for 5 days
Study: 34857397
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (three regimens)
Study: 34547529
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injections
Study: 616411777
Drug: Subconjunctival bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival bevacizumab (1.25 mg/0.1 mL)
Study: 33382926
Drug: Tegoprazan 50
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50 mg administered 30 min before a high-fat meal
Study: 33382926
Drug: Tegoprazan 50
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50 mg administered 30 min after a high-fat meal
Study: 33382926
Drug: Tegoprazan 50
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50 mg in fasting condition
Study: 33382926
Drug: Tegoprazan 50
Normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan 50 mg administered in fasting condition
Study: 35213105
Drug: Beclomethasone dipropionate,
Normalized name: Beclomethasone Dipropionate, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate, 80 μg plus usual care
Study: 32464799
Drug: Standard immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard immunosuppressive therapy (CTR)
Study: 33358843
Drug: LCPUFA‐120 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPUFA‐120 (40 mg/kg/day DHA and 80 mg/kg/day ARA)
Study: 33358843
Drug: LCPUFA‐360 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPUFA‐360 (120 mg/kg/day DHA and 240 mg/kg/day ARA)
Study: 33176850
Drug: Surfactant (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surfactant (4 ml, equivalent to 100 mg, administered into the trachea in two doses, starting on the day of intubation with a second dose 6 hours later)
Study: 33176850
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (same volume based on weight, administered into the trachea with the same time schedule)
Study: 35947315
Drug: Active low‐level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active low‐level laser (LLL) therapy, 12 sessions
Study: 35947315
Drug: Active low‐level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active low‐level laser (LLL) therapy
Study: 32842812
Drug: L-arginine/L-citrulline (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine/L-citrulline (5 g/day)
Study: 33491528
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 200 IU, Silymarin 750 mg, and l-carnitine 1 gram (VSC) for 18 weeks
Study: 33645176
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (TRT)
Study: 33023661
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg plus MTX
Study: 33023661
Drug: CZP 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 400 mg plus MTX
Study: 33023661
Drug: CZP 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CZP 200 mg plus MTX and CZP 400 mg plus MTX
Study: 35402691
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin (UH) 50 IU/kg bolus during the procedure
Study: 33947255
Drug: Triptorelin acetate
Normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triptorelin acetate (0.1 mg) administered on the day of embryo transfer along with routine luteal support
Study: 33801251
Drug: Caffeine at
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine at a dose of 9 mg/kg body mass
Study: 32702849
Drug: Fusu mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusu mixture combined with Western medicine
Study: 33403738
Drug: Low-concentration carbohydrate
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-concentration carbohydrate solution (300 mL) taken 2 hours before induction of anesthesia
Study: 35120284
Drug: Methylphenidate (MPH;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (MPH; 20 mg/d)
Study: 35675498
Drug: Intensive sliding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive sliding scale insulin (correction for BG >140 mg/dL)
Study: 35675498
Drug: Nonintensive sliding
Normalized name: benzalkonium chloride Topical Foam [DigiClean Slim-Line]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonintensive sliding scale insulin (correction for BG >260 mg/dL)
Study: 35675498
Drug: Intensive sliding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive sliding scale insulin
Study: 35675498
Drug: Nonintensive sliding
Normalized name: benzalkonium chloride Topical Foam [DigiClean Slim-Line]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonintensive sliding scale insulin
Study: 34976760
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam with intranasal S-ketamine
Study: 33059647
Drug: Multi-interventional program
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-interventional program including mechanical bowel preparation with oral antibiotics, tailored full splenic flexure mobilization, and intraoperative fluorescence angiography using indocyanine green.
Study: 35340337
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of lidocaine (Group L)
Study: 35835822
Drug: Third dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third dose of BBV152 (COVAXIN®)
Study: 35835822
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of BBV152 (COVAXIN®)
Study: 36064489
Drug: Interdisciplinary treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interdisciplinary treatments including psychology, physiotherapy, and medical interventions for up to 12 weeks
Study: 32222056
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump education curriculum
Study: 33640008
Drug: Machine learning
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Machine learning model for predicting flare probability after tapering bDMARDs
Study: 33640008
Drug: Percent dose
Normalized name: Polyacrylamide (crosslinked; 2 mole percent bisacrylamide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percent dose change of bDMARDs
Study: 33106259
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CON) of fosfomycin at 1 g/h preceded by a loading dose of 8 g over 30 min
Study: 33106259
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion (INT) of fosfomycin at 8 g over 30 min every 8 h
Study: 32383366
Drug: Lactobacillus pentosus
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus pentosus (1.0 × 10^10 CFU daily for 12 weeks)
Study: 32359046
Drug: Unit-dose packaging
Normalized name: zolmitriptan
DrugBank: Zolmitriptan (DB00315)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unit-dose packaging
Study: 35382772
Drug: Midwifery-led counseling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midwifery-led counseling (six 60-90 min sessions, twice a week)
Study: 34343968
Drug: non-PCA (Hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-PCA (Hydromorphone Titration by Healthcare Provider)
Study: 34471087
Drug: Danhong injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danhong injection (DHI) for 14 days
Study: 32521115
Drug: Suture ligation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suture ligation with suspension
Study: 36027311
Drug: High salt
Approvals — FDA: no, EMA: no, PMDA: no
Description: High salt intake (HIS: 200 mmol/day of sodium tablets)
Study: 35671829
Drug: Crushed tablets
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed tablets of prasugrel
Study: 35671829
Drug: Integral tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integral tablets of prasugrel
Study: 33740926
Drug: Avapritinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avapritinib (300 mg or 400 mg)
Study: 33740926
Drug: Other tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Other tyrosine kinase inhibitors (TKIs)
Study: 36223849
Drug: 0.19-mg fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.19-mg fluocinolone acetonide (FAc) intravitreal implant
Study: 33827306
Drug: 5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 µg Dex intrathecally
Study: 33827306
Drug: 5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 µg sufentanil intrathecally
Study: 33827306
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL saline (0.9%) intrathecally
Study: 32843240
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure (PE) therapy delivered in person
Study: 32843240
Drug: Prolonged Exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged Exposure (PE) therapy delivered via telemedicine
Study: 32093379
Drug: Resveratrol (manufacturer’s
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (manufacturer’s recommended dose)
Study: 34167897
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg nolasiban
Study: 34167897
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg nolasiban
Study: 35288393
Drug: Emicizumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emicizumab (3 mg/kg once per week for the first 4 weeks, followed by 1.5 mg/kg once per week, 3 mg/kg once every 2 weeks, or 6 mg/kg once every 4 weeks)
Study: 33389422
Drug: Corneal collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corneal collagen cross‐linking treatment
Study: 32299845
Drug: Riociguat 0.5
Normalized name: riociguat 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riociguat 0.5 mg to 2.5 mg orally three times daily (n=60)
Study: 35669656
Drug: Scalpel treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalpel treatment (group B)
Study: 35669656
Drug: Lateral crypt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral crypt block treatment (group A)
Study: 35902888
Drug: Substance Use
Normalized name: reSET Substance Use Disorder Therapy Software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substance Use Treatment and Recovery Team (START) intervention
Study: 33757520
Drug: BDP/FF/G (beclometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF/G (beclometasone dipropionate 100 µg, formoterol fumarate 6 µg, glycopyrronium 10 µg) via pressurised metered-dose inhaler, two puffs twice-daily for 24 weeks
Study: 33757520
Drug: BUD/FF (budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FF (budesonide 160 µg, formoterol fumarate 4.5 µg) via dry-powder inhaler, two puffs twice-daily for 24 weeks
Study: 39140777
Drug: Diphenhydramine (DPH)
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diphenhydramine (DPH) 50 mg
Study: 33825828
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol maleate solution, 0.5%, applied twice daily for 24 weeks
Study: 33825828
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice daily for 24 weeks
Study: 33825828
Drug: Topical timolol
Normalized name: timolol
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical timolol maleate solution, 0.5%
Study: 33328284
Drug: Combo (50%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combo (50% basal rate reduction set at exercise onset with carbohydrate intake of 0.3 g/kg/h)
Study: 33328284
Drug: CHO-only (usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO-only (usual basal rate with carbohydrate intake of 0.3 g/kg/h)
Study: 32895369
Drug: JNJ-61393215 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-61393215 (90 mg)
Study: 32895369
Drug: JNJ-61393215 (dose-dependent)
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-61393215 (dose-dependent)
Study: 33478571
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (penetration needling of Hand‐Yangming meridian, PNHM) for 16 weeks
Study: 33478571
Drug: Observation period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation period for 16 weeks followed by 16 weeks of compensation PNHM therapy
Study: 33478571
Drug: Acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture therapy (PNHM)
Study: 34511596
Drug: Fast wean
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast wean arm (abrupt discontinuation of NCPAP from 6 cmH2O)
Study: 32487334
Drug: Intratympanic dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intratympanic dexamethasone injection
Study: 33023898
Drug: Metformin adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin adherence (≥80%)
Study: 33023898
Drug: Metformin adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin adherence
Study: 33023898
Drug: Early adherence
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early adherence to metformin
Study: 36134465
Drug: Decaffeinated green
Normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated green coffee extract (DGCE) supplementation, 400 mg capsules, two capsules daily for 12 weeks
Study: 36134465
Drug: Placebo, two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, two identical capsules daily for 12 weeks
Study: 35537641
Drug: Continued conservative
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued conservative treatment
Study: 35537641
Drug: Transaxillary thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transaxillary thoracic outlet decompression (TA‐TOD) after conservative treatment
Study: 35296912
Drug: TS-142 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-142 5 mg
Study: 35296912
Drug: TS-142 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-142 10 mg
Study: 35296912
Drug: TS-142 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: TS-142 30 mg
Study: 616508090
Drug: Tablet condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet condition (using a stylus and electronic tablet)
Study: 35260419
Drug: imlifidase (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: imlifidase (0.25 mg/kg single dose)
Study: 34252387
Drug: e‐health‐based screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: e‐health‐based screening strategy consisting of repetitive one‐minute photoplethysmographic (PPG) pulse wave assessments using a certified smartphone app (Preventicus Heartbeats), followed by a confirmatory 14‐day ECG patch (CardioMem CM 100 XT) in case of abnormal findings.
Study: 33023495
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml 0.5% ropivacaine (Group A)
Study: 33023495
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml normal saline (Group B)
Study: 36749332
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg aflibercept
Study: 33217861
Drug: Home-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based therapy (HBT)
Study: 32314891
Drug: Digital guide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital guide plate (51 implants)
Study: 32314891
Drug: Routine implant
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine implant restoration treatment (45 implants)
Study: 35544369
Drug: mRNA-1273 vaccine
Normalized name: SARS-CoV-2 mRNA-1273 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 vaccine (50 μg each)
Study: 34653002
Drug: Vojta therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vojta therapy (specific tactile input)
Study: 32020400
Drug: Microwave ablation
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microwave ablation plus chemotherapy
Study: 36991381
Drug: Intermittent esketamine
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intermittent esketamine infusion (6-hour intravenous infusion every 2 weeks for 3 months, starting at 0.05 mg/kg/h, max 0.2 mg/kg/h)
Study: 36991381
Drug: Continuous esketamine
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Continuous esketamine infusion (6 consecutive days of intravenous infusion)
Study: 36991381
Drug: Intermittent esketamine
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intermittent esketamine infusion
Study: 33456366
Drug: Chlorpheniramine maleate
Normalized name: Chlorpheniramine Maleate
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine maleate (CPM) 8 mg intravenous before induction of anesthesia
Study: 32144735
Drug: Preoperative endocrine
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative endocrine therapy concurrent with chemotherapy for 24 weeks
Study: 35651610
Drug: G-CSF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (5 μg/kg every day for 6 days, then every other day until day 18)
Study: 34117198
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of CYD‐TDV and Tdap vaccine
Study: 34117198
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of CYD‐TDV and Tdap vaccine
Study: 34117198
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (concomitant and sequential)
Study: 34477139
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection and splint treatment
Study: 33885235
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg astaxanthin orally daily
Study: 33758940
Drug: Vegetable Intervention
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable Intervention (VI) - daily provision of vegetables in amounts and types recommended by the DGA (∼270 g/day) for 8 weeks
Study: 35241176
Drug: Functional standing
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional standing frame programme (30 min. standing plus sit‐to‐stand repetitions) plus 15 min of usual physiotherapy daily
Study: 35241176
Drug: Usual physiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual physiotherapy (45 min) daily
Study: 35768113
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg daily for 8 weeks preoperatively
Study: 35768113
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules daily for 8 weeks preoperatively
Study: 34282985
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis with alteplase (baseline ≥5 cerebral microbleeds)